Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UBA52P7 (ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 7) is a processed pseudogene in humans that originated from the UBA52 gene, which normally encodes a ubiquitin-ribosomal fusion protein[2][4][6]. Pseudogenes such as UBA52P7 contain sequence defects (such as deletions or mutations) that disrupt their coding capacity, so they do not produce functional protein products[4][5][6]. Pseudogene families corresponding to ubiquitin genes are common in mammals, resulting from gene duplication and retrotransposition events. Most are non-transcribed and have no known functional or disease associations[4][5][6]. UBA52P7 may sometimes be referenced in genetic or genomic databases, but it is not therapeutically relevant. While isolated reports suggest an emerging interest in some ubiquitin pseudogenes for possible regulatory RNA roles or rare cryptic function, there is no current evidence or consensus for such a role for UBA52P7[5][6].
Not applicable for this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 7 (UBA52P7).